Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables (2016 - 2025)

Historic Receivables for Fortress Biotech (FBIO) over the last 11 years, with Q3 2025 value amounting to $18.0 million.

  • Fortress Biotech's Receivables rose 6852.22% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year increase of 6852.22%. This contributed to the annual value of $10.2 million for FY2024, which is 3322.67% down from last year.
  • Latest data reveals that Fortress Biotech reported Receivables of $18.0 million as of Q3 2025, which was up 6852.22% from $15.6 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Receivables high stood at $32.1 million for Q3 2021, and its period low was $8.0 million during Q3 2023.
  • For the 5-year period, Fortress Biotech's Receivables averaged around $20.4 million, with its median value being $18.9 million (2021).
  • In the last 5 years, Fortress Biotech's Receivables skyrocketed by 24205.17% in 2021 and then tumbled by 7200.08% in 2023.
  • Over the past 5 years, Fortress Biotech's Receivables (Quarter) stood at $24.7 million in 2021, then rose by 21.84% to $30.1 million in 2022, then tumbled by 49.11% to $15.3 million in 2023, then crashed by 33.23% to $10.2 million in 2024, then skyrocketed by 75.77% to $18.0 million in 2025.
  • Its Receivables stands at $18.0 million for Q3 2025, versus $15.6 million for Q2 2025 and $18.0 million for Q1 2025.